2023-11-09 03:37:16
08:43 PM
The Ministry of Health and Social Protection says it is ready to start applying the Bivalent BA4/BA5 vaccine once morest Covid-19, produced in Moderna laboratories. Therefore, they hope to begin the distribution process in mid-November, taking into account the recommendations of the World Health Organization (WHO) and the indications of the National Institute for Food and Drug Surveillance (Invima).
Therefore, Minsalud will administer the vaccine to the Colombian population, also adopting the guidelines of the Health Authorization for Emergency Use (ASUE), in order to prioritize the supply of the biologicals currently available. The first and main one is that they are people aged 18 years and over, and that in the last six months they have received at least one dose of the vaccine to combat Covid-19, and secondly, patients with comorbidities, who are over 60 years old or are part of the health personnel.
The schedule planned by the Ministry of Health, in order to prioritize the elderly population at risk, will be between November 2023 and April 2024, and this measure is intended to reinforce the vaccination strategy that has already been advanced by the health entity throughout the national territory, through the Expanded Immunization Program, through which the country has permanently had vaccines and boosters in more than 3,000 inoculation points throughout Colombia.
Thus, Minsalud expects to apply regarding 757,400 doses of the Bivalent vaccine from the Moderna Laboratory in the coming days.
What are Bivalent vaccines?
The only bivalent vaccines developed so far are the versions from Moderna, Spikevax and Pfizer-BioNTech, Comirnaty; and they began to be approved at the end of 2022, when a good part of the world’s population had completed their entire vaccination and reinforcement schedule once morest the virus, but it continued to mutate, so it began to become necessary to look for another form of immunization. more effective.
Some specialists, such as Peter Marks, director of the FDA’s Center for Biological Evaluation and Research, pointed out last year during a press conference for several American media outlets that the goal with this updated vaccine was to spread the time of protection once morest the disease, especially in the population most vulnerable to the virus.
The above, following cases of Covid-19 infection were increasing in countries such as the United States and the United Kingdom, nations where the first tests were carried out on patients, until good results were achieved.
“The hope is that by increasing the amount of antibodies we have once morest the omicron variant, in particular, we will restore the type of protection we had with the first vaccines released in late 2020 and early 2021,” Marks said.
So they hope, with these new biologics, to save as many lives as possible over time. Because with them they seek to reduce the number of hospitalizations and deaths, prioritizing the population that is at greater risk of contracting the virus despite having some versions of the biological in their body.
1699504092
#Minsalud #announced #month #distribution #bivalent #vaccine #covid19
